Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
William A FahyFarshid Homayoun-ValianiAnthony CahnJon RobertsonAlison TempletonWilhelmine H MeerausRobert WilsonMike LowingsMiriam MarottiSarah L WestMaggie TabbererEdith M HesselPublished in: International journal of chronic obstructive pulmonary disease (2021)
The addition of nemiralisib to standard-of-care treatment for 12 weeks did not improve lung function or re-exacerbations in patients with, and following an acute exacerbation of COPD. However, this study demonstrated that large clinical trials recruiting acutely exacerbating patients can successfully be conducted.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- cystic fibrosis
- clinical trial
- liver failure
- respiratory failure
- healthcare
- air pollution
- end stage renal disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- chronic kidney disease
- placebo controlled
- randomized controlled trial
- drug induced
- quality improvement
- double blind
- acute respiratory distress syndrome
- phase iii
- smoking cessation
- replacement therapy
- phase ii study
- locally advanced